PhD The development of Next-Gen Microfluidics and Bioinformatics approaches for the Characterisation of Superior Biopharmaceuticals
Lead Research Organisation:
University College London
Department Name: Biochemical Engineering
Abstract
Although microfluidic analytics has been employed in small molecule medicine development, it has not been used for applications related to biopharmaceutical entities and processes. Also there are no bioinformatics tools available for predicting molecule behaviours during manufacturing and formulation development.
This collaborative PhD project between UCL and GSK will aim to develop novel analytical approaches for monitoring the quality of biopharmaceuticals during bioprocess manufacturing. It will develop appropriate micro-scale technologies to meet the requirements of the modern biopharmaceutical development landscape. It will evaluate current analytical approaches in terms of sample requirements, sensitivity, throughput, requirement for sample preparation. It will then adapt the most promising techniques to bring it closer to a capability in automated online bioprocess monitoring. Finally, the project will use the datasets (built from the micro-scale technology) to support the design and development of computational tools and technologies with application to address the challenges outlined above.
This collaborative PhD project between UCL and GSK will aim to develop novel analytical approaches for monitoring the quality of biopharmaceuticals during bioprocess manufacturing. It will develop appropriate micro-scale technologies to meet the requirements of the modern biopharmaceutical development landscape. It will evaluate current analytical approaches in terms of sample requirements, sensitivity, throughput, requirement for sample preparation. It will then adapt the most promising techniques to bring it closer to a capability in automated online bioprocess monitoring. Finally, the project will use the datasets (built from the micro-scale technology) to support the design and development of computational tools and technologies with application to address the challenges outlined above.
People |
ORCID iD |
| Paul Dalby (Primary Supervisor) |
 http://orcid.org/0000-0002-0980-8167
|
Studentship Projects
| Project Reference | Relationship | Related To | Start | End | Student Name |
|---|---|---|---|---|---|
| BB/N503903/1 | 01/10/2015 | 30/09/2019 | |||
| 1637263 | Studentship | BB/N503903/1 | 01/10/2015 | 27/09/2019 |
| Description | A fluorescence based assay has been proposed to evaluate the manufacturability of monoclonal antibodies (mAbs). The assay is to be used to triage a panel of mAbs, based on their propensity to aggregate due to thermal degradation or concentration dependence, and identify potential problems early on in the development process. |
| Exploitation Route | Others may use the assay to generate data, from a large panel of mAbs, to then use in silico methods to detect trends and identify root causes of aggregation. |
| Sectors | Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology |